The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
ConclusionOverall, PH FDC SC demonstrated potential economic and organizational advantages for hospitals and patients compared with P+T IV, even though patients treated subcutaneously experienced longer waits between activities, indicating the need for optimized organizational choices.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | HER2 | Herceptin | Italy Health | Study